MetaVia Inc.

MTVASEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1638287

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Operating Income (Loss)	-$15.9M	-$19.6M	-$15.3M	-$29.7M	-$20.2M
Other Nonoperating Income (Expense)	$3.4M	$5.7M	$14.0K	-$1.0K	-$1.0K
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$12.5M	-$14.0M	-$15.3M	-$29.7M	-$21.3M
Income Tax Expense (Benefit)	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income (Loss) Attributable to Parent	-$12.5M	-$14.0M	-$15.3M	-$29.7M	-$21.3M
Earnings Per Share, Basic	-$2.46	-$43.42	-$19.81	-$1.83	—
Earnings Per Share, Diluted	-$2.46	-$43.42	-$19.81	-$1.83	—

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Assets	$22.8M	$33.5M	$16.8M	$11.0M	$14.5M
Assets, Current	$22.5M	$33.5M	$16.6M	$10.7M	$14.1M
Cash and Cash Equivalents, at Carrying Value	$22.4M	$33.4M	$16.4M	$10.1M	$13.9M
Liabilities	$6.1M	$11.8M	$2.2M	$3.8M	$2.2M
Liabilities, Current	$6.0M	$11.8M	$2.2M	$3.7M	$2.1M
Accounts Payable, Current	$821.0K	$708.0K	$830.0K	$2.6M	$638.0K
Stockholders' Equity Attributable to Parent	$21.8M	$14.6M	$7.2M	$12.3M

Concept	FY2024	FY2023	FY2022	FY2021	FY2020
Net Cash Provided by (Used in) Operating Activities	-$10.8M	-$11.7M	-$15.1M	-$10.8M	-$7.0M
Net Cash Provided by (Used in) Investing Activities	-$50.0K	$8.0K	-$586.0K	$69.0K	-$6.1M
Net Cash Provided by (Used in) Financing Activities	-$80.0K	$28.7M	$22.0M	$6.9M	$24.2M
Payments to Acquire Property, Plant, and Equipment	$50.0K	$50.0K	$3.0K	$4.0K	$214.0K

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)